Epithalon and telomeres – what we know from research

In 1971, Soviet biologist Vladimir Khavinson began a research program in St. Petersburg (then Leningrad) whose framework hypothesis sounded seemingly speculative: if the aging process is partly regulated by signals from the endocrine glands, then isolating these signals and administering them to old animals should extend their lifespan. Khavinson focused particularly on pineal gland — a gland producing melatonin, the activity of which decreases dramatically with age. He isolated a peptide fraction from the pineal extract, which he named epithalamine, and after decades of structural analysis, identified a short tetrapeptide representing its biological activity. This is how he was born Epithalon — a synthetic analogue of a peptide with the sequence Ala-Glu-Asp-Gly.

For the wider context of anti-aging research, see peptides in aging and regeneration research.

Half a century later, Epithalon is one of the most frequently discussed anti-aging peptides in popular science literature and one of the most controversial in the gerontological community. On the one hand, there is a bibliography containing dozens of studies on animal models, suggesting an extension of life by 20–30%, a reduction in spontaneous carcinogenesis, and a delay in oestropause. On the other hand, almost all the literature comes from one research group (Khavinson syndrome and related), independent replications are rare, and human studies do not meet the standards of modern phase III clinical trials.

This article gathers the current state of knowledge about Epithalon from a research perspective – what is known, what the data suggest, what remains hypothesized, and what the methodological limitations of the available literature are. It is part of a broader review anti-aging peptides.

📖 The following article is educational in nature and is a critical review of published scientific literature about Epithalon. Most of the cited studies come from animal models, some from human studies with limited methodology. The text does not constitute medical advice. Peptides from the One Peptides catalog are intended only for laboratory tests (Research Use Only).

What is Epithalon – sequence, structure, origin

Epithalon (also known as Epitalon, AEDG or Epithalamin) is tetrapeptide about the sequence:

Ala-Glu-Asp-Gly (alanine-glutamic acid-aspartic acid-glycine)

Key molecular parameters

Origin – from epithalamine to synthetic AEDG

Natural epithalamine (Epithalamin) is a mixture of peptides isolated from the pineal gland of calves – currently withdrawn from research due to difficulties in standardization. Epithalon is a synthetic tetrapeptide representing the biological activity of epithalamine, possible to produce while maintaining GMP/RUO standards.

Epithalon belongs to a broader class of peptides developed by the Institute of Bioregulation and Gerontology in St. Petersburg – peptides referred to in Russian literature as “bioregulators” or “Khavinson peptides“. Other peptides in this family include:

• Vilon — Lys-Glu (thymus peptide)
• Thymalin / Thymulin — thymus peptides
• Cortexin — cerebral cortex peptide
• Cardialin — heart peptide
• Pinealon — pineal peptide

A common feature of this class of peptides is the postulated ability to penetrate the nuclear membrane and directly interact with DNA – which goes beyond standard receptor pharmacology.

Mechanism of action – a controversial but specific hypothesis

Khavinson and his colleagues hypothesized that Epithalon and related bioregulatory peptides do not act through classical membrane receptors but rather directly on DNA and the transcription level. Mechanisms proposed in the literature include:

1. Telomerase activation

The most cited and most frequently discussed mechanism is the stimulation of telomerase activity – the enzyme responsible for the extension of telomeres (the ends of chromosomes that shorten during each cell division).

Khavinson’s laboratory in a work from 2003 showed in cell cultures (Khavinson et al., 2003):

• Increase in telomerase activity in somatic cells after incubation with Epithalon
• Telomere lengthening by approximately 33% after 6 passage cycles
• Increased cell viability beyond the standard Hayflick limit

Telomerase in most human somatic cells is inactivated – only a small subpopulation of cells expresses it (embryonic, hematopoietic, some stem cells). Inactivation of telomerase is one of the mechanisms of protection against cancer (cells with active telomerase can “escape” senescence and continue to divide, which increases the risk of carcinogenesis).

The hypothesis that Epithalon activates telomerase in somatic cells is therefore important from two perspectives – therapeutic (potential extension of regenerative capacity) and safety (potential increase in the risk of carcinogenesis).

2. Modulation of promoter methylation

More recent work suggests that Epithalon modulates the epigenetic landscape of the cell—altering the DNA methylation profile at the promoters of genes related to aging, stress response, and DNA repair. This mechanism seems more consistent with modern molecular biology than the earlier “direct interaction with DNA” hypothesis.

3. Modulation of anti-aging gene expression

Transcriptomic analyzes suggest that Epithalon changes the expression profile of hundreds of genes – with a preference towards profiles characteristic of younger cells. Specific paths:

• Increased TERT expression — telomerase
• Modulation of p53/p16/p21 genes — senescence trails
• Impact on the expression of sirtuins (SIRT1, SIRT3) — related to longevity
• Impact on oxidative stress genes

The state of animal research – what the literature says

Long-term mouse models

The most cited work on Epithalon concerns the effect on mouse lifespan. Anisimov and colleagues (various publications 1998–2010) reported long-term cyclic administration in the CBA mouse model (female):

• Increase in life expectancy — by about 24% in the experimental group
• Reduction of spontaneous carcinogenesis — lower frequency of spontaneous tumors in the Epithalon group
• Delayed oestropause — longer reproductive period in females
• Improvement of behavioral parameters — in tests on older people

Anisimov VN, Khavinson VK (2010) – summary review of the effects of bioregulatory peptides – summarizes a series of studies in various mouse lines with a consistent effect of prolonging life by 15–30%.

Rat models

Rat models are fewer in number but consistent. Reported effects include:

• Improving behavioral parameters in tests for older people
• Modulation of the hormonal profile (melatonin, cortisol)
• Increased activity of antioxidant enzymes
• Improving sleep architecture

In vitro models – telomeres and telomerase

Work on cultures of human fibroblasts and other cell lines:

• Khavinson et al. (2003) — the work on telomerase activation described above
• Goncharova et al. (2005) — the effect of Epithalon on hormonal functions in older animals
• Kossoy et al. (2006) — modulation of spontaneous carcinogenesis in a mouse model

Collectively, the in vitro literature suggests that Epithalon at nanomolar concentrations modulates the phenotype of old cells towards a “younger” profile—without specific indication of the mechanism at the signaling pathway level.

Methodological criticism – important reservations

Before turning to human studies, several important methodological caveats must be made regarding all available Epithalon literature.

Geography of publications and the issue of replication

The vast majority of work on Epithalon comes from one research center — Institute of Bioregulation and Gerontology in Saint Petersburg and closely cooperating groups. Independent replications by Western teams are very limited. This does not invalidate the results, but it lowers their epistemic importance.

In standard scientific work, important discoveries require independent replications in different laboratories with different methodologies before they become accepted scientific fact. Epithalon—with a bibliography that includes hundreds of publications, but mostly from a single group—stays on the line between fascinating hypothesis and established biological fact.

Magazines with limited impact

Some of the key publications on Epithalon appeared in journals with a low impact factor or in Russian-language publications that were poorly accessible to the Western scientific community. This makes evaluation by international peer review difficult.

Lack of standardization of models

The different studies on Epithalon used different doses, administration schedules, and animal models – without a consistent standard that would allow results to be compared between studies.

⚠️ These methodological caveats do not invalidate the results—they only suggest that the Epithalon literature requires careful interpretation. Conclusions about the extension of human lifespan, modulation of telomerase in vivo or anti-aging effects in humans remain in the experimental hypothesis phase.

Research on humans – controversies and limitations

Khavinson’s work – long-term follow-up of 266 people

The most frequently cited human study of Epithalon is Khavinson and colleagues’ long-term follow-up of 266 older adults. Parameters:

• Experimental group: cyclic administration of Epithalon and Thymalin for 6 months/year for 6–8 years
• Control group: standard care
• Observation period: 6–12 years

Reported results:

• Lower mortality in the experimental group
• Improvement of selected biochemical parameters
• Subjective reporting of well-being

Criticism of this work

Methodological criticism includes:

• Lack of proper randomization — selection into groups was not consistent with contemporary standards
• No blind test — participants and doctors knew who was receiving the peptide
• There is no placebo with a comparable form of administration
• Heterogeneity of control groups
• Possible selection bias — people continuing the study may have had better health parameters regardless of Epithalon

According to the standards of modern pharmacology, this work would not meet the requirements for registration as a medicine. As a ‘signal observation’ – indicating an area requiring further study – it may have value, but conclusions about a causal effect of Epithalon require caution.

No phase III trials

Unlike incretin peptides (semaglutide, retatrutide) with an extensive Phase III trial database, Epithalon does not have any clinical trials that meet these standards. The lack of drug registration with the EMA, FDA, or other major jurisdictions is not a coincidence – it reflects the limitations of available clinical data.

Analytical specification of Epithalon from the One Peptides catalog

Epithalon 10 mg as a research reagent from the One Peptides catalog, it meets the following quality criteria:

Each vial is marked with a batch number associated with a certificate of analysis (COA). Full QC documentation is available on the website quality tests and certificates.

Stability and storage

Epithalon is a relatively stable peptide:

• Lyophilisate: Stability 24 months at -20°C
• Solution after reconstitution in bacteriostatic water: 21–28 days in a refrigerator at 2–8°C
• Sensitivity to freeze/thaw cycles: moderate

A complete guide to storing and reconstituting peptides in the overview article on laboratory practice of peptides.

Security – what results from the literature

In animal models, Epithalon showed a favorable safety profile – in the work of Khavinson’s group, no significant organ toxicity was reported in long-term administration protocols.

However, an important caveat should be taken into account:

⚠️ Hypothetical telomerase activation by Epithalon raises the question about the potential risk of carcinogenesis. Inactivation of telomerase in somatic cells is one of the mechanisms of protection against cancer – cells with active telomerase can “escape” senescence and continue to divide. If Epithalon does activate telomerase systemically, the long-term risk of carcinogenesis requires further characterization. Animal data paradoxically suggest a reduction in spontaneous carcinogenesis, but extrapolation to humans remains uncertain.

The oncological safety of peptides that may activate telomerase remains an open research question.

FAQ – Frequently asked questions

Epithalon available in the One Peptides catalog with full QC documentation. Check Epithalon 10 mg.

Bartosz BartczakPhysiotherapist, Personal Trainer

Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective content.

See Full Bio ›